Alexion Pharma (ALXN) Tops Q1 EPS by 15c; Raises Outlook

Alexion Pharma (NASDAQ: ALXN) reported Q1 EPS of $1.38, $0.15 better than the analyst estimate of $1.23. Revenue for the quarter came in at $870 million versus the consensus estimate of $827.2 million.

• 1Q17 Total Revenues of $870 Million, a 24% Increase and 26% Volume Increase Year-Over-Year
• Revenue Growth Benefited from Continued Strong Volume Growth of Soliris® In Core Markets
• Strensiq® Revenue Driven by Steady Addition of New Patients Starting Treatment
• Applications Filed in U.S., Europe and Japan for Soliris in Patients with Refractory gMG
• Enrollment in ALXN1210 Phase 3 Studies Advanced in Patients with PNH and aHUS
• New Phase 1 Data Support Advancing Development of ALXN1210 Subcutaneous Formulation
• Reiterating 2017 Revenue Guidance of $3.4 to $3.5 Billion and Increasing GAAP EPS Guidance to $2.80 to $3.20 per share and Non-GAAP EPS Guidance to $5.10 to $5.30 per share

""We delivered continued double-digit revenue growth in the quarter from our complement and metabolic portfolios and achieved important regulatory milestones towards the potential approval of Soliris as a treatment for patients with refractory gMG in the U.S., Europe and Japan. We also demonstrated strong commercial execution for Soliris while simultaneously enrolling patients with PNH and aHUS into the ALXN1210 Phase 3 trials," said Ludwig Hantson, Chief Executive Officer of Alexion. "Alexion’s strong performance in the first quarter positions us well for continued success in 2017 and beyond. As we continue to grow our business, we will be anchored by a culture of compliance and driven by passion and dedication to patients. I am excited to work with our team to capitalize on Alexion’s fundamentals to drive continued momentum and long-term growth by enhancing our commercial, R&D and capital allocation priorities to drive superior financial performance and shareholder returns."

GUIDANCE:

Alexion Pharma sees FY2017 EPS of $5.10-$5.30, versus the consensus of $5.23.

For earnings history and earnings-related data on Alexion Pharma (ALXN) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15
• Movano (MOVE) Misses Q2 EPS by 195c